Literature DB >> 19557418

[New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany].

.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19557418     DOI： 10.1007/s00347-009-1969-2

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  34 in total

1.  [Comments on current therapeutic possibilities for neovascular age-related macula degeneration].

Authors: 
Journal:  Klin Monbl Augenheilkd       Date:  2006-04       Impact factor: 0.700

2.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration.

Authors:  Mark S Hughes; Delia N Sang
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2006 Nov-Dec

4.  Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.

Authors:  David R Fintak; Gaurav K Shah; Kevin J Blinder; Carl D Regillo; John Pollack; Jeffrey S Heier; Hussein Hollands; Sanjay Sharma
Journal:  Retina       Date:  2008 Nov-Dec       Impact factor: 4.256

Review 5.  A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

Authors:  Jan S A G Schouten; Ellen C La Heij; Carroll A B Webers; Igor J Lundqvist; Fred Hendrikse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-09       Impact factor: 3.117

6.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

7.  Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.

Authors:  Michael S Ip; Ingrid U Scott; Gary C Brown; Melissa M Brown; Allen C Ho; Suber S Huang; Franco M Recchia
Journal:  Ophthalmology       Date:  2008-10       Impact factor: 12.079

8.  [Intravitreous injection: retrospective study on 2028 injections and their side effects].

Authors:  M C Angulo Bocco; A Glacet-Bernard; A Zourdani; G Coscas; G Soubrane
Journal:  J Fr Ophtalmol       Date:  2008-09       Impact factor: 0.818

9.  Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.

Authors:  Samer E Farah
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2008 Jul-Aug

10.  RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD.

Authors:  Maria Andreea Gamulescu; Carsten Framme; Helmut Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-21       Impact factor: 3.535
View more
  5 in total

1.  [Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain].

Authors:  H Heimann; Y Yang; J Wachtlin; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

2.  [Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014].

Authors: 
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

3.  [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].

Authors:  D Pauleikhoff; B Bertram; D Claessens
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

4.  [Intravitreal injections of medications in Germany. Contract situation and legal conditions].

Authors:  F Ziemssen; P Wiedemann; A Kampik; F Holz; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

5.  [Access to healthcare services for elderly patients with neovascular age-related macular degeneration].

Authors:  R P Finger; F G Holz
Journal:  Ophthalmologe       Date:  2012-05       Impact factor: 1.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.